UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): May 6, 2015

 

Cleveland BioLabs, Inc.
(Exact Name of Issuer as Specified in Charter)

 

DELAWARE   001-32954   20-0077155
(State or Other Jurisdiction of
Incorporation or Organization)		   (Commission File Number)   (I.R.S. Employer
Identification Number)

 

73 High Street
Buffalo, NY 14203
(Address of Principal Executive Offices and zip code)

 

(716) 849-6810
(Registrant's Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Conditions.

 

On May 6, 2015, Cleveland BioLabs, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2015. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit No.  Description
    
99.1  Press Release titled “Cleveland BioLabs Reports First Quarter 2015 Financial Results and Development Progress”, dated May 6, 2015

  

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Cleveland BioLabs, Inc.
     
Date: May 6, 2015 By:

/s/ YAKOV KOGAN 

  Name: Yakov Kogan
  Title: Chief Executive Officer

 

 

 

3